聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 28 分钟 26 秒 前

FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer

周一, 04/11/2016 - 12:49
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Applicat...
Biopharmaceuticals, Personalized Medicine, Oncology, FDA
Genentech, Roche Group, atezolizumab, NSCLC, Cancer Immunotherapy

Voluntary Recall of Fetch(TM) 2 Aspiration Catheter

周五, 04/08/2016 - 21:41
MARLBOROUGH, Mass., April 8, 2016 -- (Healthcare Sales & Marketing Network) -- Boston Scientific (NYSE: BSX) has initiated a global, voluntary recall of all models of its Fetch™ 2 Aspiration Catheter, a thrombectomy catheter used during procedures to remo...
Devices, Interventional, Cardiology, Product Recall
Boston Scientific, Fetch 2, Aspiration Catheter, thrombectomy

Avion Pharmaceuticals, LLC, announces appointment of new Chief Executive Officer

周五, 04/08/2016 - 15:09
ATLANTA, April 8, 2016 -- (Healthcare Sales & Marketing Network) -- Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, is pleased to announce the appointment of Harold A. Deas, Jr. as Chief Executive Officer. Mr. Deas, who will retain his rol...
Biopharmaceuticals, Dermatology, Personnel
Avion Pharmaceuticals

Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease

周五, 04/08/2016 - 15:06
Phase 2/3 trial of AZD3293, an oral potent small molecule BACE inhibitor, will continue to Phase 3 after positive interim safety data INDIANAPOLIS, April 8, 2016 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) and AstraZeneca t...
Biopharmaceuticals, Neurology
Eli Lilly, AstraZeneca, beta secretase cleaving enzyme, Alzheimer's

Pharming Announces Adoption by the European Commission of the CHMP Recommendation to Change the Terms of the Marketing Authorisation for Ruconest(R)

周四, 04/07/2016 - 15:28
TREATMENT OF HAE ATTACKS IN ADOLESCENTS WITH HAE APPROVED IGE TESTING REQUIREMENTS REMOVED LEIDEN, The Netherlands, April 7, 2016 -- (Healthcare Sales & Marketing Network) -- Pharming Group N.V. ("Pharming" or "the Company") (PHA...
Biopharmaceuticals, Regulatory
Pharming Group, RUCONEST, Hereditary Angioedema

PhaseBio Announces Leadership Team Appointments

周四, 04/07/2016 - 15:24
John S. Lee, M.D., Ph.D., named Chief Medical Officer John P. Sharp, CPA, named Chief Financial Officer MALVERN, Pa., April 07, 2016 -- (Healthcare Sales & Marketing Network) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical comp...
Biopharmaceuticals, Cardiology, Personnel
PhaseBio Pharmaceuticals, elastin-like polypeptide

St. Jude Medical Announces the European Launch of the Trifecta Surgical Valve with Glide Technology to Improve Options for Patients in Need of Aortic Valve Replacement

周四, 04/07/2016 - 15:19
The new Trifecta™ Valve with Glide™ Technology provides enhanced valve delivery designed to improve implantation during both minimally invasive and conventional valve replacement procedures ST. PAUL, MN, April 7, 2016--(Healthcare Sales & Marketing Netw...
Devices, Cardiology, Product Launch
St. Jude Medical, Trifecta Valve, aortic valve

VolitionRx Announces CE Marks for Two NuQ(R) Blood Assays for Detection of Colorectal Cancer

周四, 04/07/2016 - 15:16
CE Mark Enables European Clinical Use and Sale in 33 Countries to up to 600 million people NAMUR, Belgium, April 7, 2016 -- (Healthcare Sales & Marketing Network) -- VolitionRx Limited (NYSE MKT: VNRX) today announced CE marking for two blood-based dia...
Diagnostics, Oncology, Regulatory
VolitionRx, NuQ, colorectal cancer

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

周四, 04/07/2016 - 15:11
MISSISSAUGA, ON, April 7, 2016 -- (Healthcare Sales & Marketing Network) - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two ph...
Biopharmaceuticals, Dermatology, Personnel
Cipher Pharmaceuticals

Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai Inc.

周三, 04/06/2016 - 15:19
WOODCLIFF LAKE, N.J., April 6, 2016 -- (Healthcare Sales & Marketing Network) -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Paul Hawthorne to the position of Senior Vice President, U.S. ...
Biopharmaceuticals, Neurology, Personnel
Eisai

Janssen Enters Worldwide Collaboration and License Agreement with TESARO, Inc., for Niraparib in Prostate Cancer

周三, 04/06/2016 - 15:10
RARITAN, N.J., April 6, 2016 -- (Healthcare Sales & Marketing Network) -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today it has entered a worldwide collaboration and license agreement with TESARO, ...
Biopharmaceuticals, Oncology, Licensing
Janssen, Johnson & Johnson, TESARO, niraparib, breast cancer, ovarian cancer

Allergan Reiterates Strong Standalone Growth Profile and Strategy Following Termination of Pfizer Transaction

周三, 04/06/2016 - 15:06
Pfizer-Allergan Merger Agreement Terminated Allergan's Leading Commercial Franchises, 70+ Mid-to-Late Stage Pipeline Projects to Fuel Continued Strong Top-Line Growth in 2016 and Beyond Powerful Financial Profile and Balance Sheet Provides Optionalit...
Biopharmaceuticals, Mergers & Acquisitions
Allergan, Pfizer

Pfizer Announces Termination of Proposed Combination with Allergan

周三, 04/06/2016 - 15:04
NEW YORK, NY--(Healthcare Sales & Marketing Network)--Pfizer Inc. (PFE) today announced that the merger agreement between Pfizer and Allergan plc (AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announc...
Biopharmaceuticals, Mergers & Acquisitions
Pfizer, Allergan

Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients

周三, 04/06/2016 - 15:02
Novel liquid biopsy RAS testing now available to clinical practices for metastatic colorectal cancer (mCRC) patients The test will help guide physicians to select the most effective treatment for mCRC patients in a timely manner DARMSTADT, Germany, ...
Diagnostics, Oncology, Regulatory
Merck, Sysmex Inostics, OncoBEAM, colorectal cancer

Sorrento Appoints Kevin M. Herde As Chief Financial Officer

周三, 04/06/2016 - 14:57
SAN DIEGO, April 5, 2016 -- (Healthcare Sales & Marketing Network) -- Sorrento Therapeutics, Inc. (SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, today annou...
Biopharmaceuticals, Personnel
Sorrento Therapeutics, resiniferatoxin

Premia Spine Launches ProMIS(TM) Fixation System

周二, 04/05/2016 - 13:37
First Skin-to-Screw Pedicle Screw Placement System with sterile-pack implants PHILADELPHIA, April 5, 2016 -- (Healthcare Sales & Marketing Network) -- Premia Spine, a spinal implant company focused on commercializing innovative lumbar solutions, today ...
Devices, Orthopaedic, Neurosurgery, Product Launch
Premia Spine, ProMIS Fixation System, Pedicle Screw, spine surgery

Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

周二, 04/05/2016 - 13:30
NEW YORK--(Healthcare Sales & Marketing Network)--Pfizer Inc. announced today top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic arthritis, Oral Psoriatic Arthritis triaL (OPAL) Broaden. This study evalua...
Biopharmaceuticals
Pfizer, tofacitinib, XELJANZ, psoriatic arthritis

Ability Dynamics Introduces the Dynamic, Ultra Low Profile RUSH ROVER(TM) for Active Amputees

周二, 04/05/2016 - 13:19
TEMPE, Ariz., April 5, 2016 -- (Healthcare Sales & Marketing Network) -- Ability Dynamics, LLC a developer of next-generation prosthetic devices announced today the release of the ultra low profile RUSH ROVER™ prosthetic foot. Determined to remain at t...
Devices, Orthopaedic, Product Launch
Ability Dynamics, RUSH ROVER, prosthetic foot

Braeburn Pharmaceuticals and Camurus Announce Enrollment Goals Reached in Two Pivotal Phase 3 Trials of Cam2038 for Treatment of Opioid Dependence

周二, 04/05/2016 - 13:11
PRINCETON, N.J. and LUND, Sweden, April 5, 2016 -- (Healthcare Sales & Marketing Network) -- Braeburn Pharmaceuticals and Camurus today announced that the enrollment goals for both the 24-week efficacy study and the 48-week safety study were met on 31 Mar...
Biopharmaceuticals
Braeburn Pharmaceuticals, Camurus, CAM2038, Opioid Dependence

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong